Last reviewed · How we verify
Early Caffeine administration
At a glance
| Generic name | Early Caffeine administration |
|---|---|
| Sponsor | Hospital de Clinicas de Porto Alegre |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) (PHASE2)
- Comparison Of VR & CPT, With And Without Lifestyle Modification, On ULD In Breast Cancer Survivors (NA)
- Comparison of Early Caffeine Administration Vs Supportive Therapy in Preventing Acute Kidney Injury (NA)
- Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants (NA)
- Biomarker-enhanced Artificial Intelligence Based Pediatric Sepsis Screening Tool
- Restorative Early Sleep Treatment After the Emergency Department (NA)
- Xofluza-Wearables Feasibility-Study (PHASE4)
- The Caffeine Therapy in the Fetal to Neonatal Transition (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Early Caffeine administration CI brief — competitive landscape report
- Early Caffeine administration updates RSS · CI watch RSS
- Hospital de Clinicas de Porto Alegre portfolio CI